View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 16, 2022

Trevi ends enrolment early in Phase II IPF chronic cough trial after positive interim data

Haduvio offered a 77.3% decline in daytime cough frequency from baseline versus a 25.7% in the placebo arm, interim data showed.

Trevi Therapeutics concluded enrolment early in the Phase II CANAL trial of Haduvio (nalbuphine ER) to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The decision to conclude comes after the company previously revealed statistically significant efficacy interim assessment data from the trial.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The interim analysis was carried out on 26 trial subjects, validating the proof of concept. Nearly 40 participants were enrolled in the trial.

On the primary efficacy endpoint, treatment with Haduvio offered a 77.3% decline in the frequency of daytime cough from baseline versus a 25.7% decline in the placebo arm.

This interim data indicated a 52% placebo-adjusted decline in the geometric mean percent change in the frequency of daytime cough.

The trial centres were alerted to enrol eligible subjects who were being screened without needing further recruitment.

Trevi anticipates efficacy and safety data from the full set of participants in the third quarter of this year.

Haduvio is an oral extended-release formulation of nalbuphine, which is a combined ĸ-opioid receptor agonist and µ-opioid receptor antagonist.

Injectable nalbuphine is approved for use in the US and Europe and is marketed for pain indications for over two decades.

The randomised, double-blind, placebo-controlled, two-treatment, two-period crossover trial in the UK is analysing the safety and efficacy of nalbuphine ER for chronic cough in IPF patients. 

It has two treatment periods of three weeks, with a washout period of two weeks following each treatment period. 

Analysing the impact of nalbuphine ER tablets on the mean daytime cough frequency at day 22 versus placebo as assessed by an objective cough monitor is the trial’s primary efficacy endpoint.

In February this year, the company concluded subject enrolment in the Phase IIb/III PRISM trial of Haduvio for pruritus associated with prurigo nodularis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena